6-K 1 a7698d.htm NOTICE OF ANNUAL GENERAL MEETING (AGM) a7698d
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of April 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
 04 April 2025 - Notice of Annual General Meeting (AGM)
 
 
99.1
 
Haleon plc: Notice of Annual General Meeting (AGM)
 
4 April 2025: Haleon plc (the "Company" or "Haleon") today announces that the following documents have been made available to shareholders:
 
1.  Notice of 2025 Annual General Meeting (the "Notice");
2.  Form of Proxy for 2025 Annual General Meeting; and
3.  AGM Voting Instruction Card.
 
Haleon's AGM will again be a virtual meeting, broadcast under studio conditions from the Company's London offices at 3.00pm (BST) on Wednesday 28 May 2025. The Notice is available on the Company's website at https://www.haleon.com/investors/shareholder-information/annual-general-meetings, and includes full details of the business to be conducted and joining instructions.
 
In compliance with UK Listing Rule 6.4.1R, a copy of the above documents has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
Amanda Mellor
Company Secretary
 
Enquiries
 
Investors
Media
 
Jo Russell
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Emma White
+44 7823 523562
 
 
 
Email: investor-relations@haleon.com
 
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com. 
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: April 04, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary